Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal tumours: Case reports

Annals of Oncology

Volumn 20, Issue SUPPL.1, 2009, Pages

  Schoffski P ^a   Bukowski, R ^b   Flodgren, P ^c   Ravaud, A ^d  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d HÔPITAL SAINT ANDRÉ   (France)

Author keywords

Gastrointestinal stromal tumour; Metastatic renal cell carcinoma; Sunitinib malate; Tyrosine kinase inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRROLE DERIVATIVE; SUNITINIB;

AGED; ARTICLE; CASE REPORT; DRUG ANTAGONISM; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; INTESTINE TUMOR; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; SMALL INTESTINE;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; INTESTINAL NEOPLASMS; INTESTINE, SMALL; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROTEIN-TYROSINE KINASES; PYRROLES;

EID: 66549086138     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp076     Document Type: Conference Paper

References (26)

1. Ljungberg B, Hanbury FC, Kuczyk MA et al. Guidelines on Renal Cell Carcinoma. Update March 2007 http://www.uroweb.org/fileadmin/user_upload/Guidelines/08_Renal_Cell_Car cinoma_2007(accessed 3 August 2008).
2. Pfizer Inc. SUTENT® (sunitinib): Summary of Product Characteristics January 2008.
3. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
4. Figlin RA, Hutson TE, Tomczak P et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 2008; 26 (May 20 Suppl): Abstr 5024; Oral presentation.
5. Reichardt P, Kang Y, Ruka W et al. Detailed analysis of survival and safety with sunitinib (SU) in a worldwide treatment-use trial of patients with advanced GIST. J Clin Oncol 2008; 26: 565s Abstr 10548; Poster presentation.
6. Casali PG, Jost L, Reichardt P et al. Gastrointestinal stromal tumors: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19 (Suppl 2): ii35-ii38.
7. O'Farrell AM, Foran JM, Fiedler W et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003; 9: 5465-5476.
8. Houk BE, Bello CL, Michaelson MD et al. A population pharmacokinetic/pharmacodynamic (PK/PD) analysis of exposure-response for sunitinib in metastatic renal cell carcinoma (mRCC). Presented at the 14th European Cancer Conference, 23-27. Barcelona: Spain September 2007.
9. Demetri GD, Casale PG, Bello C et al. A population pharmacokinetic/pharmacodynamic (PK/PD) meta-analysis of sunitinib in patients with gastrointestinal stromal tumour. Presented at the 19th International Congress on Anti-Cancer Treatment, 5-8. Paris, France February 2008.
10. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-1338.
11. Motzer RJ, Bacik J, Murphy BA et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289-296.
12. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alpha-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111.
13. Rini BI, Halabi S, Rosenberg JE et al. CALGB 90206: a phase III trial of bevacizumab plus interferon-alfa versus interferon-alfa monotherapy in metastatic renal cell carcinoma. San Francisco, CA, USA: Oral presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium February 14-16, 2008 Abstr 350.
14. Hornick JL, Fletcher CDM. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hum Pathol 2007; 38: 679-687.
15. Rubin BP. Gastrointestinal stromal tumours: an update. Histopathology 2006; 48: 83-96.
16. D'Amato G, Steinert DM, McAuliffe JC et al. Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control 2005; 12: 44-56.
17. Din OS, Woll PJ. Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate. Ther Clin Risk Manag 2008; 4: 149-162.
18. Hoeben A, Schöffski P, Debiec-Rychster M. Clinical implications of mutational analysis in gastrointestinal stromal tumours. Brit J Cancer 2008; 98: 684-688.
19. Antonescu CR, Besmer P, Guo T et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005; 11: 4182-4190.
20. Debiec-Rychter M, Sciot R, Le Cesne A et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42: 1093-1103.
21. Heinrich MC, Corless CL, Demetri GD et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-4349.
22. Heinrich MC, Maki RG, Corless CL et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib malate in imatinib-resistant gastrointestinal stomal tumours. J Clin Oncol 2008; e-pub ahead of print: doi/10.1200/JCO.2007.15.7461.
23. Porta C, Szczylik C, Bracarda S et al. Short- and long-term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma. J Clin Oncol 2008; 26 (May 20 Suppl): Abstr 5114; Poster presentation.
24. Négrier S, Ravaud A. Optimisation of sunitinib therapy in metastatic renal cell carcinoma: adverse-event management. Eur J Cancer 2007; 5 (Suppl): 12-19.
25. Ravaud A. How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents. Ann Oncol 2008; 20 (Suppl 1): i7-i12.
26. Robert C, Soria JC, Spatz A et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6: 491-500.